Cantin André M
Pulmonary Division, Department of Medicine, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, Quebec, Canada.
Ann Am Thorac Soc. 2016 Apr;13 Suppl 2:S150-5. doi: 10.1513/AnnalsATS.201509-588KV.
Cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) have traditionally been viewed as two distinct entities of unrelated origins. However, molecular, cellular, and clinical studies have revealed that cystic fibrosis transmembrane conductance regulator (CFTR) protein dysfunction is common to both conditions, one (CF) being defined genetically and the other (COPD) as an acquired CFTR deficiency. Multiple molecular mechanisms of cigarette smoke-induced CFTR dysfunction have been reported. More importantly, considerable evidence of cigarette smoke-induced CFTR dysfunction in several respiratory and nonrespiratory tissues have been confirmed, making CFTR a target that cannot be overlooked in our quest to understand COPD and improve therapies for individuals affected by this disease. This review summarizes the molecular, cellular, and clinical evidence that CFTR dysfunction is induced by cigarette smoke exposure both in vitro and in vivo, and explores how this may contribute to the development of COPD.
传统上,囊性纤维化(CF)和慢性阻塞性肺疾病(COPD)被视为起源无关的两种不同疾病。然而,分子、细胞和临床研究表明,囊性纤维化跨膜传导调节因子(CFTR)蛋白功能障碍在这两种疾病中都很常见,其中一种(CF)由基因定义,另一种(COPD)为后天性CFTR缺乏。已有报道称香烟烟雾诱导CFTR功能障碍存在多种分子机制。更重要的是,香烟烟雾诱导CFTR功能障碍在多个呼吸和非呼吸组织中的大量证据已得到证实,这使得CFTR成为我们在理解COPD并改善受该疾病影响个体的治疗方法的过程中不可忽视的一个靶点。本综述总结了CFTR功能障碍在体外和体内均由接触香烟烟雾诱导的分子、细胞和临床证据,并探讨了这可能如何促进COPD的发展。